Henry Schein's broader growth, recurring technology revenues and savings plan support its outlook, but leverage and execution risks remain key concerns.

ALGN's record Clear Aligner growth and global adoption support the bull case, but demand softness and scanner pricing pressure keep investors cautious.

Envista raises 2026 guidance as stronger sales and expanding margins lift earnings, but China pricing, tariffs and a tougher Q4 loom.

DENTSPLY SIRONA's Q2 sales fall 4.1% as dental weakness offsets Wellspect growth, while margins improve and 2026 guidance is maintained.

The headline numbers for Dentsply (XRAY) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Dentsply (XRAY) delivered earnings and revenue surprises of +44.44% and +1.60%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

McKesson (MCK) delivered earnings and revenue surprises of +5.19% and +0.95%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

XRAY's Q2 results are likely to reflect transformation investments, dealer inventory cuts and weak implants, while Wellspect growth offers support.

Conmed (CNMD) delivered earnings and revenue surprises of +25.46% and +1.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?